• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Stem Cells

Orchard Therapeutics, UCLA land $20m for stem cell clinical trial

November 23, 2016 By Sarah Faulkner

Orchard Therapeutics, UCLA land $20m for stem cell clinical trial

Orchard Therapeutics and researchers from the University of California Los Angeles Broad Stem Cell Research have been awarded $20 million from the California Institute for Regenerative Medicine’s governing to fund a clinical trial for adenosine deaminase deficiency. The rare, inherited disorder is caused by mutations in a gene that encodes for adenosine deaminase. This results […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Immunotherapy, Stem Cells Tagged With: Orchard Therapeutics, University of California Los Angeles

Zimmer Biomet touts preliminary data for stem cell therapy

November 15, 2016 By Sarah Faulkner

Zimmer Biomet (NYSE:ZBH) touted data today from an investigational device exemption trial evaluating the use of autologous concentrated bone marrow aspirate for the treatment of critical limb ischemia. The stem cell study is the 1st pivotal trial of its kind to complete enrollment and a 1-year follow-up in a patient population that is ineligible for revascularization, […]

Filed Under: Clinical Trials, Featured, Regulatory/Compliance, Stem Cells Tagged With: Zimmer Biomet

Stanford uses CRISPR to correct sickle cell, human trials planned

November 8, 2016 By Sarah Faulkner

Stanford Medicine

Researchers from the Stanford University School of Medicine have reportedly used CRISPR, a gene-editing tool, to repair the gene that causes sickle cell disease. The team is planning the 1st human clinical trial using this technique to correct cells with sickle cell disease, according to Reuters.  “What we’ve finally shown is that we can do it. It’s […]

Filed Under: Clinical Trials, Featured, Research & Development, Stem Cells Tagged With: Broad Institute, Stanford University, University of California Berkeley

SanBio touts 1-year data on stem cell transplant for stroke

November 4, 2016 By Sarah Faulkner

SanBio touts 1-year data on stem cell transplant for stroke

SanBio Inc. (TYO:4592) released 1-year interim data from the phase 1/2a, open-label, single-arm dose escalation study of its intracerebral stem cell implant designed for stroke patients. The Mountain View, Calif.-based company touted the results, which indicated that itsSB623 stem cell treatment was generally safe, well-tolerated and associated with improved motor functions in patients  suffering with chronic impairment following […]

Filed Under: Clinical Trials, Featured, Neurological, Research & Development, Stem Cells Tagged With: SanBio Inc

FDA OKs stem cell-gene therapy trial for ALS

October 28, 2016 By Sarah Faulkner

FDA OKs stem cell, gene therapy trial for ALS

The FDA approved a combination stem cell-gene therapy clinical trial to test the treatment’s ability to slow the progression of amyotrophic lateral sclerosis. It’s the 1st clinical trial to use neural stem cells to deliver a particular protein in the hopes of slowing ALS progression, according to researchers at the ALS clinic at Cedars-Sinai Medical […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Stem Cells Tagged With: ALS Association, Cedars-Sinai Medical Center

Researchers boost stem cell programming with gene mutation

October 25, 2016 By Sarah Faulkner

Researchers discovered a way to increase the efficiency of stem cell programming using research on a rare genetic disease, according to a study published in the Proceedings of the National Academy of Sciences.  Induced pluripotent stem cells are created from skin cells and can be transformed into any type of cell in the body. Using existing […]

Filed Under: Featured, Research & Development, Stem Cells

Targazyme wins FDA clearance for Phase II bone marrow stem cell study

October 25, 2016 By Sarah Faulkner

Targazyme wins FDA clearance for Phase II bone marrow stem cell study

Targazyme said today that it will begin enrolling patients in a Phase II clinical study to evaluate TZ101-fucosylated bone marrow stem cells in cancer patients, after the FDA granted the San Diego-based company investigational new drug clearance. The treatment is designed to use blood-forming stem cells from bone marrow to restore the body’s ability to make blood […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Stem Cells Tagged With: Targazyme Inc

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS